Loading…
Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications
Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cell...
Saved in:
Published in: | Frontiers in immunology 2018-04, Vol.9, p.784-784 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c462t-bb93eafbb4a4ed292014609a8477d62ec47da74a63e8455a7d74d7dc19d5f0a13 |
---|---|
cites | cdi_FETCH-LOGICAL-c462t-bb93eafbb4a4ed292014609a8477d62ec47da74a63e8455a7d74d7dc19d5f0a13 |
container_end_page | 784 |
container_issue | |
container_start_page | 784 |
container_title | Frontiers in immunology |
container_volume | 9 |
creator | Yang, Sujuan Wang, Julie Brand, David Douglass Zheng, Song Guo |
description | Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF
TNFR1 mainly triggers pro-inflammatory pathways, and mTNF binding to TNFR2 usually initiates immune modulation and tissue regeneration. TNFα plays a critical role in upregulation or downregulation of Treg activity. Deficiency in TNFR2 signaling is significant in various autoimmune diseases. An ideal therapeutic strategy for autoimmune diseases would be to selectively block the sTNF/TNFR1 signal through the administration of sTNF inhibitors, or using TNFR1 antagonists while keeping the TNFR2 signaling pathway intact. Another promising strategy would be to rely on TNFR2 agonists which could drive the expansion of Tregs and promote tissue regeneration. Design of these therapeutic strategies targeting the TNFR1 or TNFR2 signaling pathways holds promise for the treatment of diverse inflammatory and degenerative diseases. |
doi_str_mv | 10.3389/fimmu.2018.00784 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_621c32ac198d4a23bdfa6642ee8a9679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_621c32ac198d4a23bdfa6642ee8a9679</doaj_id><sourcerecordid>2035240238</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-bb93eafbb4a4ed292014609a8477d62ec47da74a63e8455a7d74d7dc19d5f0a13</originalsourceid><addsrcrecordid>eNpVkUFr3DAQhUVpaEKSe09Fx168kSXZsi6FsjTNQmgg2UJvYiyNNwq25Up2IP--ym4aEoHQMJr3aTSPkM8lWwnR6IvOD8Oy4qxsVoypRn4gJ2Vdy0JwLj--iY_JeUoPLC-phRDVJ3LMteKV4M0J-XMbeqSho9tfl0Xe9BYtTnOIlNM7vxuhp37Myd3SQ84-0S1dY98nCqOjmznR7T1GmHCZvaWbYeq9hdmHMZ2Row76hOcv5yn5fflju74qrm9-btbfrwsraz4XbasFQte2EiQ6rvN3ZM00NFIpV3O0UjlQEmqBjawqUE5Jp5wttas6BqU4JZsD1wV4MFP0A8QnE8CbfSLEnYGYm-vR1Ly0gkPWNk4CF63rIA-JIzaga6Uz69uBNS3tgM7iOEfo30Hf34z-3uzCo6l0WWvFMuDrCyCGvwum2Qw-2TwvGDEsyXAmKi4ZF00uZYdSG0NKEbvXZ0pmnv01e3_Ns79m72-WfHnb3qvgv5viH82RoYY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2035240238</pqid></control><display><type>article</type><title>Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications</title><source>PubMed Central</source><creator>Yang, Sujuan ; Wang, Julie ; Brand, David Douglass ; Zheng, Song Guo</creator><creatorcontrib>Yang, Sujuan ; Wang, Julie ; Brand, David Douglass ; Zheng, Song Guo</creatorcontrib><description>Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF
TNFR1 mainly triggers pro-inflammatory pathways, and mTNF binding to TNFR2 usually initiates immune modulation and tissue regeneration. TNFα plays a critical role in upregulation or downregulation of Treg activity. Deficiency in TNFR2 signaling is significant in various autoimmune diseases. An ideal therapeutic strategy for autoimmune diseases would be to selectively block the sTNF/TNFR1 signal through the administration of sTNF inhibitors, or using TNFR1 antagonists while keeping the TNFR2 signaling pathway intact. Another promising strategy would be to rely on TNFR2 agonists which could drive the expansion of Tregs and promote tissue regeneration. Design of these therapeutic strategies targeting the TNFR1 or TNFR2 signaling pathways holds promise for the treatment of diverse inflammatory and degenerative diseases.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2018.00784</identifier><identifier>PMID: 29725328</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>autoimmune diseases ; Immunology ; regulatory T cells ; tumor necrosis factor receptor 1 ; tumor necrosis factor receptor 2 ; tumor necrosis factor α</subject><ispartof>Frontiers in immunology, 2018-04, Vol.9, p.784-784</ispartof><rights>Copyright © 2018 Yang, Wang, Brand and Zheng. 2018 Yang, Wang, Brand and Zheng</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-bb93eafbb4a4ed292014609a8477d62ec47da74a63e8455a7d74d7dc19d5f0a13</citedby><cites>FETCH-LOGICAL-c462t-bb93eafbb4a4ed292014609a8477d62ec47da74a63e8455a7d74d7dc19d5f0a13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916970/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916970/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29725328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Sujuan</creatorcontrib><creatorcontrib>Wang, Julie</creatorcontrib><creatorcontrib>Brand, David Douglass</creatorcontrib><creatorcontrib>Zheng, Song Guo</creatorcontrib><title>Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF
TNFR1 mainly triggers pro-inflammatory pathways, and mTNF binding to TNFR2 usually initiates immune modulation and tissue regeneration. TNFα plays a critical role in upregulation or downregulation of Treg activity. Deficiency in TNFR2 signaling is significant in various autoimmune diseases. An ideal therapeutic strategy for autoimmune diseases would be to selectively block the sTNF/TNFR1 signal through the administration of sTNF inhibitors, or using TNFR1 antagonists while keeping the TNFR2 signaling pathway intact. Another promising strategy would be to rely on TNFR2 agonists which could drive the expansion of Tregs and promote tissue regeneration. Design of these therapeutic strategies targeting the TNFR1 or TNFR2 signaling pathways holds promise for the treatment of diverse inflammatory and degenerative diseases.</description><subject>autoimmune diseases</subject><subject>Immunology</subject><subject>regulatory T cells</subject><subject>tumor necrosis factor receptor 1</subject><subject>tumor necrosis factor receptor 2</subject><subject>tumor necrosis factor α</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUFr3DAQhUVpaEKSe09Fx168kSXZsi6FsjTNQmgg2UJvYiyNNwq25Up2IP--ym4aEoHQMJr3aTSPkM8lWwnR6IvOD8Oy4qxsVoypRn4gJ2Vdy0JwLj--iY_JeUoPLC-phRDVJ3LMteKV4M0J-XMbeqSho9tfl0Xe9BYtTnOIlNM7vxuhp37Myd3SQ84-0S1dY98nCqOjmznR7T1GmHCZvaWbYeq9hdmHMZ2Row76hOcv5yn5fflju74qrm9-btbfrwsraz4XbasFQte2EiQ6rvN3ZM00NFIpV3O0UjlQEmqBjawqUE5Jp5wttas6BqU4JZsD1wV4MFP0A8QnE8CbfSLEnYGYm-vR1Ly0gkPWNk4CF63rIA-JIzaga6Uz69uBNS3tgM7iOEfo30Hf34z-3uzCo6l0WWvFMuDrCyCGvwum2Qw-2TwvGDEsyXAmKi4ZF00uZYdSG0NKEbvXZ0pmnv01e3_Ns79m72-WfHnb3qvgv5viH82RoYY</recordid><startdate>20180419</startdate><enddate>20180419</enddate><creator>Yang, Sujuan</creator><creator>Wang, Julie</creator><creator>Brand, David Douglass</creator><creator>Zheng, Song Guo</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180419</creationdate><title>Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications</title><author>Yang, Sujuan ; Wang, Julie ; Brand, David Douglass ; Zheng, Song Guo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-bb93eafbb4a4ed292014609a8477d62ec47da74a63e8455a7d74d7dc19d5f0a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>autoimmune diseases</topic><topic>Immunology</topic><topic>regulatory T cells</topic><topic>tumor necrosis factor receptor 1</topic><topic>tumor necrosis factor receptor 2</topic><topic>tumor necrosis factor α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Sujuan</creatorcontrib><creatorcontrib>Wang, Julie</creatorcontrib><creatorcontrib>Brand, David Douglass</creatorcontrib><creatorcontrib>Zheng, Song Guo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Sujuan</au><au>Wang, Julie</au><au>Brand, David Douglass</au><au>Zheng, Song Guo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2018-04-19</date><risdate>2018</risdate><volume>9</volume><spage>784</spage><epage>784</epage><pages>784-784</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 is ubiquitously expressed on almost all cells, while TNFR2 exhibits a limited expression, predominantly on regulatory T cells (Tregs). In addition, the signaling pathway by sTNF
TNFR1 mainly triggers pro-inflammatory pathways, and mTNF binding to TNFR2 usually initiates immune modulation and tissue regeneration. TNFα plays a critical role in upregulation or downregulation of Treg activity. Deficiency in TNFR2 signaling is significant in various autoimmune diseases. An ideal therapeutic strategy for autoimmune diseases would be to selectively block the sTNF/TNFR1 signal through the administration of sTNF inhibitors, or using TNFR1 antagonists while keeping the TNFR2 signaling pathway intact. Another promising strategy would be to rely on TNFR2 agonists which could drive the expansion of Tregs and promote tissue regeneration. Design of these therapeutic strategies targeting the TNFR1 or TNFR2 signaling pathways holds promise for the treatment of diverse inflammatory and degenerative diseases.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>29725328</pmid><doi>10.3389/fimmu.2018.00784</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1664-3224 |
ispartof | Frontiers in immunology, 2018-04, Vol.9, p.784-784 |
issn | 1664-3224 1664-3224 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_621c32ac198d4a23bdfa6642ee8a9679 |
source | PubMed Central |
subjects | autoimmune diseases Immunology regulatory T cells tumor necrosis factor receptor 1 tumor necrosis factor receptor 2 tumor necrosis factor α |
title | Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A11%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20TNF-TNF%20Receptor%202%20Signal%20in%20Regulatory%20T%20Cells%20and%20Its%20Therapeutic%20Implications&rft.jtitle=Frontiers%20in%20immunology&rft.au=Yang,%20Sujuan&rft.date=2018-04-19&rft.volume=9&rft.spage=784&rft.epage=784&rft.pages=784-784&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2018.00784&rft_dat=%3Cproquest_doaj_%3E2035240238%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-bb93eafbb4a4ed292014609a8477d62ec47da74a63e8455a7d74d7dc19d5f0a13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2035240238&rft_id=info:pmid/29725328&rfr_iscdi=true |